Zacks Research Issues Optimistic Forecast for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Zacks Research raised their Q1 2025 EPS estimates for shares of BioMarin Pharmaceutical in a research report issued on Wednesday, March 12th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings of $0.69 per share for the quarter, up from their previous estimate of $0.61. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q2 2025 earnings at $0.79 EPS, Q3 2025 earnings at $0.90 EPS, Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $3.30 EPS, Q1 2026 earnings at $0.91 EPS, Q3 2026 earnings at $1.07 EPS, Q4 2026 earnings at $1.16 EPS and FY2026 earnings at $4.12 EPS.

Other analysts also recently issued research reports about the stock. Citigroup upped their price target on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Piper Sandler upped their price objective on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an “overweight” rating in a research report on Thursday, February 20th. Scotiabank upped their price objective on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 20th. Royal Bank of Canada restated a “sector perform” rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $90.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

BioMarin Pharmaceutical Stock Down 0.0 %

BMRN stock opened at $71.52 on Monday. The company has a fifty day moving average price of $66.38 and a 200 day moving average price of $68.38. BioMarin Pharmaceutical has a 12 month low of $60.63 and a 12 month high of $94.85. The company has a market cap of $13.64 billion, a price-to-earnings ratio of 32.51, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million.

Insider Activity at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 1,344 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $68.38, for a total value of $91,902.72. Following the sale, the chief accounting officer now directly owns 13,105 shares of the company’s stock, valued at approximately $896,119.90. This represents a 9.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.85% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BMRN. Janney Montgomery Scott LLC lifted its holdings in BioMarin Pharmaceutical by 102.1% in the 3rd quarter. Janney Montgomery Scott LLC now owns 11,700 shares of the biotechnology company’s stock valued at $822,000 after purchasing an additional 5,911 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in BioMarin Pharmaceutical by 4.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 456,097 shares of the biotechnology company’s stock valued at $32,059,000 after purchasing an additional 20,631 shares in the last quarter. Metis Global Partners LLC lifted its holdings in BioMarin Pharmaceutical by 9.7% in the 3rd quarter. Metis Global Partners LLC now owns 5,450 shares of the biotechnology company’s stock valued at $383,000 after purchasing an additional 480 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in BioMarin Pharmaceutical by 5.6% in the 3rd quarter. CIBC Asset Management Inc now owns 6,731 shares of the biotechnology company’s stock valued at $473,000 after purchasing an additional 359 shares in the last quarter. Finally, AM Squared Ltd lifted its holdings in BioMarin Pharmaceutical by 75.0% in the 3rd quarter. AM Squared Ltd now owns 1,400 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 600 shares in the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.